Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.027 | 0.7 |
mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.031 | 0.7 |
mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |
mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.7 |
mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |